Decision on optimal combinatorinal Therapies in IMIDS using Systems approaches
The DOCTIS project has recently published several scientific publications that shed light on crucial advancements in single-cell genomics and potential therapeutic strategies for preventing severe COVID-19. One of the publications, titled “Sampling Time-Dependent Artifacts in Single-Cell Genomic Studies,” highlights the
“From the knowledge generated by the DOCTIS project we hope to make a leap in the way IMID patients are treated, and improve the long-term quality of life of thousands of patients”, DOCTIS coordinator To promote the activities of the
Milestones in combinatorial therapies The Work Package 6 of the DocTIS Project focuses its efforts in evaluating the combinatorial therapies in animal models of the different IMID’s and compare them to the approved monotherapies. To this purpose, the laboratory of
CD80/86 axis blocking agent abatacept, selected among 130 immunomodulators to be tested in ACTIV-1 IM, a large randomized clinical trial on hospitalized COVID-19 patients. The candidate drug will be tested against anti-TNF therapy, CCR2/5 inhibitor and placebo in relation to
While vaccines are being developed to stop the COVID-19 pandemic, there is a major effort to prevent the high mortality associated with COVID-19 hyperinflammation. Researchers from the Vall Hebron Hospital Research Institute and IMIDomics have contributed to this endeavour by